This study is testing two drugs, Propranolol Hydrochloride and Pembrolizumab, to see if they work well together against a type of skin cancer called melanoma. Melanoma is a serious skin cancer that can spread to other parts of the body. Some patients have melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system fight cancer more effectively, while Propranolol may help the immune system respond better under stress. The study aims to find out the best dose and observe any side effects.
- The study lasts for up to 2 years with treatments every 3 weeks.
- Participants must visit the clinic regularly for treatments and check-ups.
- Eligibility includes being newly diagnosed with specific stages of melanoma and meeting certain health criteria.
If you are eligible and decide to join, you will take propranolol by mouth twice a day and receive pembrolizumab through an IV every three weeks. After completing the study, you will be checked regularly for any health changes.
How understandable was the trial content above?
Hard to understand
Easy to understand